Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros,

 Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst
          Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, March 21, 2014

NEW YORK, March 21, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Idenix
Pharmaceuticals Inc. (NASDAQ: IDIX), BG Medicine, Inc. (NASDAQ: BGMD),
Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Omeros Corporation (NASDAQ:
OMER), and Opexa Therapeutics, Inc. (NASDAQ: OPXA). Private wealth members
receive these notes ahead of publication. To reserve complementary membership,
limited openings are available at:
http://www.AnalystsReview.com/registerhttp://www.analystsreview.com/register

http://www.analystsreview.com/register

IdenixPharmaceuticalsInc.AnalystNotes

On March 14, 2014, Idenix Pharmaceuticals Inc. (Idenix) announced that the
Company has filed patent infringement lawsuits against Gilead Sciences, Inc.
(Gilead) and/or certain of its subsidiaries in France, Germany, and the United
Kingdom. Idenix informed that the lawsuits allege that Gilead infringes the
Company's recently-granted, co-owned European patent EP 1 523 489 that covers
2'-methyl-2'-fluoro nucleosides for treating the hepatitis C virus.
Additionally, the Company stated that it is seeking remedies with respect to
Gilead's marketing and sales of drugs containing sofosbuvir, which according
to Idenix infringes the Company's European patent. Commenting on the lawsuit,
Maria Stahl, Senior Vice President and General Counsel for Idenix, stated, "We
are pleased to have been granted this European patent, and today's filings
further confirm Idenix's conviction in the strength of our intellectual
property portfolio and the resolve we have to protect it. Idenix has invested
significant resources in nucleoside drug discovery and in building a valuable
intellectual property portfolio - and we will continue to vigorously defend
it. These proceedings, along with the U.S. infringement actions we filed in
December, are part of a concerted effort to safeguard these technologies." The
full analyst notes on Idenix Pharmaceuticals Inc. are available to download
free of charge at:

http://www.AnalystsReview.com/03212014/IDIX/report.pdf

BGMedicine,Inc.AnalystNotes

On March 12, 2014, BG Medicine, Inc. (BG Medicine) reported that it welcomes
the announcement of positive top-line results by La Jolla Pharmaceutical
Company (LJPC) on March 10, 2014 of its randomized, placebo-controlled Phase 2
trial of the galectin-3 inhibitor compound GCS-100 in chronic kidney disease.
According to the Company, the trial met its primary efficacy endpoint of
improvement in kidney function and key secondary endpoints which include a
statistically significant reduction in circulating levels of galectin-3, at
the effective therapeutic dose as measured using the BGM Galectin-3® test
(developed by BG Medicine). Commenting on the results, Dr. Paul R. Sohmer,
President and CEO of BG Medicine, stated, "We welcome the important clinical
science that this Phase 2 trial represents. We look forward to the continued
advancement of the fundamental science on the biological role of galectin-3 in
health and disease." The full analyst notes on BG Medicine, Inc. are available
to download free of charge at:

http://www.AnalystsReview.com/03212014/BGMD/report.pdf

ProgenicsPharmaceuticalsInc.AnalystNotes

On March 13, 2014, Progenics Pharmaceuticals Inc. (Progenics) reported its Q4
2013 and full-year 2013 financial results. Q4 2013 total revenues decreased by
66.6% YoY to c. $3.0 million, mainly due to prior year partnering
transactions, while full-year 2013 total revenues declined by 44.0% YoY at
$7.9 million. Net loss for Q4 2013 was $8.6 million or $0.14 loss per diluted
share, compared to net loss of $0.3 million or $0.01 loss per diluted share in
Q4 2012. Net loss for full year 2013 was $42.6 million or $0.76 per diluted
share, compared to net loss of $35.4 million or $1.02 per diluted share in
full year 2012. The Company also announced that it is commencing clinical
development of MIP-1095, a PSMA-targeted small molecule radiopharmaceutical
for treating prostate cancer. The full analyst notes on Progenics
Pharmaceuticals Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03212014/PGNX/report.pdf

OmerosCorporationAnalystNotes

On March 18, 2014, Omeros Corporation's (Omeros) stock went up by 10.59%,
closing at $12.74. Over the past six-month trading session, Omeros' shares
rose 75.71%, compared to the Nasdaq Composite which gained 14.52% during the
same six-month trading session. The full analyst notes on Omeros Corporation
are available to download free of charge at:

http://www.AnalystsReview.com/03212014/OMER/report.pdf

OpexaTherapeutics,Inc.AnalystNotes

On March 18, 2014, Opexa Therapeutics, Inc.'s (Opexa) stock went up by 14.81%,
to close at $2.17. For the past five-day trading period, Opexa Therapeutics'
shares advanced 17.93%, compared to the Nasdaq Composite which gained 0.61%
during the same trading period. The full analyst notes on Opexa Therapeutics,
Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03212014/OPXA/report.pdf

AboutAnalystsReview
We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITORNOTES:

  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at pubco [at]
    AnalystsReview.com.
  oForanyurgentconcernsorinquiries, please contact us at compliance
    [at] AnalystsReview.com.
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research [at]
    AnalystsReview.com for consideration.

COMPLIANCEPROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOTFINANCIALADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.

NOWARRANTYORLIABILITYASSUMED

Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsReview.com/

SOURCE Analysts Review

Contact: CONTACT PERSON: Adam Redford, CONTACT PHONE: +852-8191-3972
 
Press spacebar to pause and continue. Press esc to stop.